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I. INTRODUCTION	 */37
The activity and metabolism of medicinal substances can be modi-
fied in animals which have been subjected to stress. The pharmacolog-
ical and biochemical consequences are functions of the nature and
intensity of the aggression, the nature of the medication and the
species and even the strain of the animal (1, 3, 12, 13, 14, 20, 21,
22 ,
---
?3, 24 2 25, 26) 27).
I
In an earlier study C91 we showed that in the rat, forced immob-
ilization brings about a potentialization of the hypnotic effects of
-r
hexobarbital and of barbital by distinct.mechanisms: inhibition of
catabolism for hexobarbital, better penetration of the blood-brain
3i	 barrier for barbital. Adding a further stress to simple restraint,
	 /38
such as an abrupt lowering of the ambient temperature which produces
a state of hypothermia, magnifies the observed potentialization by pro-
ducing a very marked increase in reactivity vis-a-vis these effectors
[19].
Does forced immobilization of the rat, whether or not accompanied
by hypothermia, lead to modification of the response to the action of
other central depressants which are not hypnotics? To contribute to
this question, in the present paper we study the influence of restraint
of rats held either at normal body temperature or at lowered body
temperature, on the effects of a muscle relaxant, zoxazolamine, whose
action is exercised through the central nervous system and which is
easily metabolized by the organism [11]. Having found an exaggeration
of the myorelaxant activity under our experimental conditions, we per-
formed determinations of zoxazolamine in the blood, brain and liver
which provide some data on the mechanism of this phenomenon.
II. TECHNIQUES
0
Zoxazolamine,	 2-aniino•5-chlorobenzoxazole,
	 o'-( I	 NH*
solubilization as the hydrochloride,	 © jl 31 1N
*Numbers in margin indicate foreign pagination.
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was used after
as a 1% aqueous
1
Wsolution. It was administrated intraperitoneally (i.p.) at a volume
ranging from 0.2 to 0.6 ml per 100 gm body weight.
The experimental animals were female rats--the action of zoxazo-
lamine is independent of sex 115,51--of the Wistar strain, aged 8 to
10 weeks and weighing 135 to 187 gm. 'hey were given water but no
food for 24 hou:s before experlment-aLion, which does not, however,
modify the activity of zoxazolamine (personal verification and [161).
Restraint was accomplished by immobilization inside a metal mesh
by the technique we have described previously [6]. Hypothermia devel-
oped during restraint when it was imposed at ambient temperatures
below that of thermal neutrality for the rat [2,4,7,18]. To maintain
ii	 the animals at normal body temperature during restraint, they were
placed in a chamber held at a temperature of 27 ± 0.5 °C. To create
more or less deep hypothermia during restraint, the animals were
placed for variable lengths of time in an environment held at 10 ±
0.5 °C [18].
At the end of restraint, which lasted from 30 minutes to 18 hours,
and no matter what the ambient temperature was during restraint, the
animals were placed at the usual laboratory temperature of 22 ± 1 °C,
treated immediately with zoxazolamine, and held in this environment	 /39
f	 for the duration of the experiment. More rarely, zoxazolamine was
administered to restrained or free rats held at 27 ± 0.5 °C.
The experiments were carried out on groups of at least 10 rats;
for each of them, unrestrained control rats were tested on the same
1	 day under the same conditions of fasting and ambient temperature as
the restrained rats.
The action of zoxazolamine is manifested by a flaccid paralysis
characterized by its latency period and its duration. The latency time
(TL) corresponds to the interval between administration of zoxazolamine
j	 and loss of postural reflexes. The duration of paralysis (DP) was
determined by measuring the time necessary for the rats, placed in
i	 2
i
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lateral decubitus, to recover reflexes of posture and . , egin to move
about. Although the animals were tested under conditions as rigor-
ously identical as possible, individual differences, often large,
were obtained for durations of paralysis; they would be a function
of the concentration of the active substance at the site of action,
the concentration itself depending in particular on the metabolic
rate, which varies from one animal to another [17]. This is why tests
must be performed on a large enough number of animals that the results
can be analyzed statistically.
The body temperature (TR) was determined by means of a thermo-
couple introduced into the sigmoid.
The presence of gastric ulcers was noted on sacrificing the
animals by decapitation, at the end of the test; the stomachs removed
were opened by an incision along the large curvature and examined
after gentle rinsing with distilled water. The percentage of rats
with ulcers was noted. The severity of the gastric attack was eva-
luated with the aid of a notation system which we have adopted in
earlier work [6,8]: 0 : normal stomach; 1 : one ulcer; 2 : two ulcers;
3 : three ulcers; 4 : four ulcers or more; the average index was cal-
culated for each group of rats.
Determination of zoxazolamine levels in the blood, brain and liver
was carried out according to the spectrophotometric technique of
Burns, Yu, Berger and Gutman [10]. In preliminary testing we confirmed
that quantities of zoxazolamine ranging from 30 to 50
	
pg added to the
blood and to cerebral and hepatic tissue are recovered with 92%
efficiency.
The presence of metabolites of zoxazolamine, 6-hydroxy-zoxazolamine,
CI-	 L_ ''N	and	 I	 N	
which respectively
^.
represent about 50% and 2% of the dose administered, does not inter-
fere with quantitation of zoxazolamine [11].
n _t
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The statistical significance of the pharmacological and bi"
chemical results was established by using the Student t test.
III. EXPERIMENTAL RESULTS
We shall compare the pharmacological and biochemical results
obtained for rats held either at normal body temperature or subjected
to hypothermia and restrained for a variable period of time, with
results for free (unrestrained) control rats held in the same ambient
temperature conditions as the restrained animals.
A. Rats restrained at normal body temperature.
To take into account- the influence of restraint by itself, we
eliminated the hypothermia which it engenders by subjecting the
animals to an ambient temperature of 27 t 0.5 °C while they were immo-
bilized. Treatment with zoxazolamine was applied at the conclusion of
restraint and the animals were then held at an ambient temperature of
22 °C or 27 °C.
	
I Pi 1 	1. Pharmacological results
a. Ambient temperature of 22 °C.
The latency period and the duration of paralysis produced by
doses of zoxazolamine ranging from 40 to 60 mg/kg were determined on
rats which had ,just undergone restraint for 135 minutes and on free
control rats (Table I).
The 40-mg/kg dose, inactive in the free rats, became effective
in 50% of the animals which had been immobilized. The 50- and 60-
mg/kg active doses produced significantly longer durations of para-
lysis (P < 0.001) in the previously restrained rats than in the free
t
controls. The potentialization observed did not intensify with the
duration of restraint. Thus, the 50-mg/kg dose 'of zoxazolamine,
which produced 26 ± 1.5 min of paralysis after 2 hr. 15 min. of res-
1
s
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traint (Table I), produced 30 t 1.7 min and 24.5 ± 2.6 min of para-
lysis in groups of 10 rats to which restraints of 4 hr. 30 min. and
18 hr., respectively, were applied.
We point out that under our experimental conditions the temper-
ature-lowering effects of zoxazolamine are identical in previously-
restrained animals and in free animals (Table I).
To determine the persistence of the potentializing effect of
restraint, we administered the 50-mg/kg dose of zoxazolamine to groups
of 10 rats at variable times after conclusion of the aggression
	
Al
(Table II). The potentialization (P < 0.001) observed in animals
tested immediately after cessation of the stress, was still manifested,
though less strongly(O.01 c P < 0.05), for 4 hours after conclusion
of restraint. 24 and 48 hrs. after conclusion of restraint., the dura-
tion of paralysis was not significantly different from that of the
free controls.
b. Ambient temperature of 27 °C.
Elevating* the temperature of the environment shortens the myorel-
axant activity of zoxazolamine [5]. Free and restrained rats sub-
jected to the action of zoxazolamine, no longer in the usual 22 °C
environment, but at the 27 °C ambient temperature, showed shorter
durations of paralysis but potentialization (0.001 < F' < 0.01) under
the Influence of restraint was always evident (Table I).
2. Biochemical results
The levels of zoxazolamine in the blood, brain and liver were	 /4L-
determined for rats in which the duration of paralysis produced by
the 50-mg/kg dose was potentialized by restraint. for 135 min. The
quantitations were made either 3.7 min (end of latency Period), or 10,
30, 60, 90 and "240 min. after auniiiilstration, of the myorelaxant . The
results were compared to those obtained for free control rats sacri-
ficed at the same intervals. All these results appear in Table III;
several observations can be made from them:
5
- at the end of the,latency period of the restrained animals (3.7
minutes), shorter than that of the free animals (5.5 minutes), the
blood and brain levels for the two groups of rats can be superposed,
although the zoxazolamine content of hepatic tissue is higher (0.01
< F < 0.05) in the stressed rats;
- 10 to 60 minutes after administration of zoxazolamine, the blood	 /43
and cerebral levels of the free and the restrained rats were not sig-
nificantly different; the hepatic level, originally higher in the res-
trained animals (to 10 min) then became equal to (at 30 min) or even
less than (at 60 min) that of the free controls;
- 90 to 240 minutes after administration of the myorelaxant, the
blood and cerebral levels c:' the restrained rats were less (0.001 <
P < 0.05) than those of the free controls while the hepatic levels
were not significantly different for the two groups of animals.
B. Rats restrained with hypothermia
The animals were subjected to a two-fold stress: restraint and
lowering of the temperature of their surroundings. The restrained
animals held at an ambient temperature of 10 °C developed a hypo-	 /44
thermia which depended on the duration of restraint; under our test
conditions, this lay between 33.7 and 24,2 °C. During their stay at
10 °C, the free control animals showed only a very slight lowering
(1 °C) of their body temperature.
1.	 Ph.armacolor-ical results
Two series of experiments were carried out to determine the
intensity and duration of the potentialization phenomenon observed
in the stressed animals.
a.	 Potentialization of the action of zoxazolamint ,	 / tlr)
At the end of the agj-session, which lasted for 30 to W9 min.,
the animals were replaced in their usual thermal environment (22 ±
1 °C) and immediately treated with zoxazolamine at doses ranrinr from
6
10 to 50 mg/kg. The results obtained are shown in Table IV.
The 50-mg/kg zoxazolamine dose which produced paralysis of free
rats which lasted 24 ± 1.4 min, had a significantly longer effect,
57 *- 2.7 min (P < 0.001) even after a short restraint of 30 min. accom-
panied by a 3.6 °C lowering of the rectal temperature. The potential-
ization is intensified with prolongation of restraint (30 to 135 min)
which in turn produces greater and greater hypothermia (33.1 and 24.2
°C). After 135 minutes of restraint, the paralysis can last 9.7
times longer than that of free control animals.
Normally inactive doses of zoxazolamine--20, 15 and even 10 mg/kg--
become effective after restraint for 90 to 120 min, which produces
hypothermia of 27.8 and 25 °C, respectively.
We also find that in stressed rats the temperature-lowering action
of zoxazolamine itself does not appear: the rectal temperature at the
end of paralysis is not significantly lower than that recorded at the
moment the myorelaxant is administered; in these animals a certain
degree of rewarming is even observed when the duration of paralysis
is long enough (Table IV).
b. Duration of potentialization.
After restraint for 90 to 135 mins. at an ambient temperature of
10 °C, the rats were held at the ambient temperature of the laboratory
(22 ± °C) and treated with zoxazolamine (20 and 50 mt./kg) at intervals
ranging f-om 1 fir to 48 firs. after cessation of stress, during which
intervals the hypothermia progressively disappeared. Free control rats
held under identical thermal conditions were tested simultaneously.
`
	
	 The results of table V show that the 20-mg/kp- dose of zoxazolamine,
ineffective to the controls and which produced paralysis in rats which
had undergone restraint for 120 minutes accompanied b,y hypothermia to
f	 25 °C, still showed an action when it was administered 3 hours after
i	 the end of stress. Four hours after the end of stress the paral,ysln7
7
action of the effector was no longer detectable.
The 50-mg/kg dose, normally effective, still had a potential-
ized action (P < 0.001) 18 hr. after cessation of stress although the
animals no longer showod any hypothermia; 24 hrs. after restraint,
the animals were still paralyzed longer than the controls tested
simultaneously, but in view of the scatter of the results, the
difference between the two groups is no longer significant (P > 0.05)./46
Finally, 48 hrs. after restraint for 135 mins., the duration of
paralysis was comparable to that for the controls (P = 0.10).
2. Biochemical results
The levels in the blood, }gain and liver were determined com-
paratively for rats w^ich had been immobilized for 120 mans. and had
hypothermia to 25 to 27 °C', and for free control rata. Two series
of experiments were carried out, using: a. the 20-mf,,/kfr dose of
zoxazolamire, ineffective in the controls but producing in the stressed
animals a duration of paralysis varying from 32 t 2.3, depending on
the group of rats, to 42 ± 4 mins. ; b. the 50-mg,/kg, dose of zoxazo-
lamine, which produced a duration of paralysis of 24 ± 1.4 min. in
the controls and 155 i 16 min. in the previously stressed animals 	 /48
(Table IV).
a. Administration of 20 mr,/kF of zoxazolamine (Table VI).
At the end of the latency period of the stressed animals (4.5
minutes), the levels of .oxazolamine in the blood and liver were higher
(0.005 < P < 0.01 and P < 0.001 respectively) than in controls sacri-
ficed at the same time, while the levels in the brain did not differ
slt7ni ficantly for the two j-roups.
Ten minutes and 35 minutes (ond of paralysis of stressed animals)
after administration, the blood, brain and liver zoxazolamine levels
were respectively hi^Ther (P < 0.001 and 0.001< P < 0.01) in the
hypert hernial restrained animals than in the control animals.
8
b. Administration of 50 mg/kg of zoxazolamine (Table VI).
The animals were sacrificed 10, 30, 90 and 240 mins. after
administration of the myorelaxant. The zoxazolamine levels in the
blood of animals restrained hypothermally remained higher (0.001 <
P < 0.01) than those of the control animals even after 4 hr; the
;
cerebral levels of the two groups of animals superposable after inter-
vals of 10 and 30 mins., were significantly higher (0.001 < P <
0.01) in the stressed animals 90 and 240 mans. after administration
of zoxazolamine; the hepatic level, higher (0.001 < P < 0.01) in
i
restrained animals 10 min. after administration of zoxazolamine, was
not significantly different from that of the controls after 30 and
90 mans. and became higher than the latter after 240 mans.
'V. RESULTS ANr DISCUSSION
This work has revealed the impact on the activity of zoxazola-
mine of an aggression consisting of forced immobilization for a more
or less long time, whether or not accompanied by hypothermia.
Potent ialization of the myorelaxant effects of zoxazolamine was
found in all stressed animals. We have established the characteris-
tics of this potentialization and attempted to elucidate its mechan-
ism by means of parmocological and biochemical testing.
We note that our results contradict those of Bousquet, Rupe and
Miya [3], who observed a shortening of the action of zoxazolamine
in animals stressed by ligature of the paw. It is probable that this
disagreement can be attributed to the difference in the nature and
intensity of the aggression to which one can also add the difference
In the rat strains tested.
a. Characteristi^s of the potentialization
	 /49
1. Immobilization
9
}To evaluate the effects produced by forced immobilization alone,
we eliminated the hypothermia which it produces by plac-Ing the test
animals and the controls ir, a chamber maintained at 27 t 0.5 °C.
Restraint for 135 mans. brought about an increase in the myorel-
axant power of zoxazolamine (P < 0.001), with the ratio of durations
of paralysis for restrained and free rats ranging from 1.7 to 2.2
(Table I). In addition, a dose of zoxazolamine inactive in all free
animals became active in 50% of the animals subjected to immobiliza-
tion: the ratio of the limiting effective doses in restrained and in
free animals was 0.8 (Table I).
Potentialization did not intensify with length or restraint,
even when it reached 18 hr-s. It persisted for at least 4 hrs. after
cessation of stress (Table II).
2. Immobilization and hypothermia
To determine the influence of immobilization accompanied by
hypothermia, we maintained the restrained animals and the controls
in a chamber at 10 t 0.5 °C. Even short restraint, 30 min., which
resulted in a lowering of body temperature by 3.6 °C, significantly
(P < 0.001) prolonged the duration of paralysis produced by zoxa-
zolamine ('Fable IV) .
The potentialization intensified with duration of restraint
and degree of hypothermia. For 135 rains. restraint, which was
accompanied by a 13 IC lowerinf; of body temperature, the ratio of
the durations of paralysis of restrained and of free rats was 9.7.
The potentializing effect persisted for at least 18 hr. after cessa-
tion of stress (Table V).
A dose of zoxazolamine inactive in normal animals became active
in stressed animals, the ratio of the limiting effective doses for
animals restrained 120 rains, with hypothermia and for control animals
was about. 0.2 ( Table IV) .
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b. Mechanism of potentialization.
Our testing has been oriented toward examining two possibilities
which could account for an increase in pharmacological activity:
slowing )^' the catabolism of the active substance, or elevation of
the sensitivity threshold of the animal toward the drug.
1. Immobilization
Under the influence of restraint, the catabolism of zoxazolamine
is not modified, at least for the duration of paralysis (Table III).
In contrast, the reactivity of the animals toward the myorelaxant is
increased. Thus, a normally ineffective dose of zoxazolamine can pro-
duce paralysis in animals which have previously been restrained
(Table I). Furthermore, determination of cerebral °oxazolamine levels
at the end of the latency period for restrained animals showed that
at identical cerebral levels, althouPh all restrained rats were para-
lyzed, 90% of the free control animals still were not (Table III).
2. Tmmobilization and hypothermia
Under the influence of restraint accompanied by hypothermia,
catabolism of zoxazolamine is slowed, especially at the cerebral
level. This slowing appears at the onset of paralysis for the 20-
mp,/kg dose (Table VI), althoui*h it appears only belatedly with the
50-mg,/kg dose--around 90 miss. after administration of the myorel-
axant (Table VI;.
The reactivity of the restrained and hypothermic animals was
considerably increased over that of normal rats. A zoxazolamine
dose only 20% of the limiting effective dose for the controls pro-
duced paralysis in rats which had been restrained with hypothermia
(Table VT).
A biochemical proof of this hypersensitivity was furnished in
particular by examination nf the cerebral zoxazolamine levels after
11
administration of a dose (20 mg/kg) which was ineffective in the con-
trols. In previously stressed animals, in which the penetration of
zoxazolamine to 'he brain is identical to that in the controls
(Table VI), paralysis developed and remained with levels very much
smaller than those necessary to produce paralysis in ncrmal animals
(Table VI).
Let us, therefore, look at the level of zoxazolamine in the brain
at the end of the latency period. In the normal animal, this level
Is constant for doses of zoxazolamine (50 and 60 mg/kg) which produce
very different durations of paralysis (21 ± 2.6 and 81 ± 7 min. res-
pectively). But in rats which have undergone restraint for 135 mins.
and a lowering of their .rectal temperature by 13.6 °C, paralysis is
engendered even by the 20-mg/kg dose of zoxazolamine, with a very
significantly lower cerebral zoxazolamine level (32 ± 3.1 ug/g
instead of 76 ± 5.5 and 80 ± 3 ug/ '?), nn.' which is equal to that for
normal animals (37 ± 1.8 u g/Q) which have been treated with the same
dose (20 mg/kg) but show no sign of paralysis (Table VII).
C. Comparison of effects produced by restraint alone and by	 /51
restraint accompanied by hypother-mia.
Restraint accompanied by hypothermia is a stress whose intensity,
much greater than that of rf straint alone, can be assessed objectively
by its consequences to the gastric mucosa, especially by the appearance
of so-called restraint ulcers. Althouj-h the rats subjected to res-
traint for 135 minx. with normal body temperatures had practically no
lesions of the gastric mucosa, amonf- the hypothermic rats restraint
for even 3O miss. led to formatlon of ulcers in 70" of the animals.
Furthermore, as Table VITI shows, gastric att.,ck interisifiPd with
length of restraint:, which In turd produced deeper and deeper hypo-
t hermia .
Thus, it is not surprisirnr- that the pharmacological consequener-s
are more severe for thypotherRi.illy-restrained rats than for those held
at normal body temperature and that in addition they lncrea_o with
length of immobilization of th y• hypothermic rinimals.
1:'
Potential ization of the myorelaxant activity of zoxazolamine by
restraint alone is small compared to that produced by immobilization
accompanied by hypothermia: the ratio of durations of paralysis for
restrained rats and free ones goes from 2.2 (normal temperature) to
9.7 (hypothermic).
As for the mechanism of potentialization, it appears that the
slowing of zoxazolamine catabolism can be attributed to the hypo-
thermia, since it is unchanged in rats restrained at normal body
temperature.
The effect of restraint on the sensitivity of the central nervous
system toward zoxazolamine is greater in animals subjected to res-
traint accompanied by hypothermia. Although a dose of zoxazolamine
201 of the normally effective dose still produces paralysis in the
latter, in animals restrained at normal body temperature It is
necessary to use a dose four times as large (80% of the limiting
effective dose for normal controls). The biochemical results confirm
this conclusion: the crebral levels of zoxazolamine which can pro-
duce and maintain paralysis can be smaller than those necessary for
rats restrained at normal body temperature (Tables III and VI).
Finally, we note that although re:'2aint, whether or not accom-
panied by hypothermia, does not change cerebral penetration of the
myor°laxant (identity of cerebral zoxazolamine levels at the end of
the latency period in restrained and in free animals, Tables III and
	
i	 VI), it does increase the permeability of liver tissue for zoxazolamine.
At the end of the latency period, and at 10 min. after administration
of the zoxazolamine, its concentration in the liver is significantly
	
s	 higher in stressed animals than in control animals (Tables III and VI).
V. CONCLUSIONS
F
1. We have established the experimental conditions which allow
zoxazolamine to exercise its myorelaxant effects on the white rat
subjected to forced immobilization, in the absence or in the presence
of hypothermia.
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2. Restraint of the white rat produces potentialization of the
myorelaxat,t activity of zoxazolamine, much stronger in the presence
of hypothermia than in its absence.
3. Determination of cerebral zoxazolamine levels in rats restrained
with and without hypothermia provides some data describing the	 /53
mechanism of the potentialization phenomenon. This is related to
the higher reactivity of the central nervous system of the rat to
zoxazolamine which is established under the influence of restraint,
and is intensified when the restraint is accompanied by hypothermia.
In hypother•mally restrained animals, a slowing of zoxazolamine catabolism
is added to this main cause.
TABLE I
Influence of restraint on duration of paralysis produced
by zoxazolamine in rats with normal body temperature.
of
animalsi,...,,••i.,,,,,,	 rt,	 iii	 i	 it;
	
treatment mg 
►, paral	 min '	 m innumber!	 yzed
TL:
In	 free	 •ut	 n
tit	 restrained	 •lu	 51)	 6	 I_i
to	 free	 so	 7?,S	 i 5,5 , 12
to	 restrained	 5n	 (J7.5	 3,2 216
i
to	 free	 an	 tuu	 ::•1	 5:1
restrained	 00	 ton	 ^ 3.3 89
",•••	 free	 Oil	 tun	 3,3	 :16
restrained	 c	 tun	 33 ao
Latency period; DP: duration of paralysis;TR:
.	 ,	 ,
"' length of restraint was 135 min
* rats held at ambient temperature of
---of 220C during paralysis.
III
.	 ..	
...	
-^ - •-- - - ^.. ... 
y v .,e c•e-..^'. ran-..-•s ^i:^
TABLE II
Duration of potentialization of zoxazolamine action
(50 mg /kg) by restraint, rats with normal body temperature
number Duration of	 P, compared
of paralysis	 to free
I.	 Free rats
	 I	 rats min.	 rats
II.
Restrained rats (*) 	20
Interval between
17 - 2,2
cessation of res-
traint & administra-
tion of zoxazo1amine
he
u	 I	 20 I	 30	 ' 6	 0,001
1	 10 I	 26	 3,2	 I	 0,050,01
10 26 - 3,6	 4	 0,05i	 0,01
4	 10 29 ± 4,6	 0,051	 0,01
24	 I	 10 25	 r 4	 0,10
42	 10 20	 2,5	 0,50
(*) Leneth of restraint was 135 min
s
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TABLE III
Influence of 135-min restraint on blood, cerebral
and hepatic levels after administration of 50 mg/kg
of zoxazolamine, rats with normal body temperature.
Interval between
	
administration I treat-	 Zoxazolamine levels (*)
of zoxazolaminel ment
and sacrifice	 of rats	 blood	 brain	 liver
m in	 Ux mi	 i	 Im x — 
_	
-	 KR a
1•',	 free	 I 37	 1,8	 61	 3,5	 Ito = 7,4
1 . "' ► restrained 41	 .5	 65	 2,3	 ! 13() 3 6,8(.)
10	 free	 32	 I,5	 5;	 3	 b5	 3
111	 is	 I,A	 (	 57	 4,a	 A3	 1,31..)restrained
A	 I	 free	 1,5	 71 ^. 6,5	 .1
all	 restrained 34 - 1,5	 I 54 _ 4	 7	 3
1	 coo
	
free
	 i	 3a	 1,.1	 61	 s	 7.1	 2,7
1111	 restrained	 34	 1,1	 01	 1.1	 of	 I,.i1...1i
1	 90	 j	 free	 ,1_	 2,13	 !	 31	 5	 6^	 S,5
	
restrained _ t	 t,; 1.) j 4u	 _,5 1.1 i 59	 3,6
u1	 free	 1"	 1,5	 36	 3,r.	 39 _ 5
111	 ;restrained 12	 1 1 . 1 i	 24	 2.41.1	 2Q	 2.4
(*) averages of 10 determinations
(**) 90% of the rats stilt not paralyzed
j(***) end of latency period, all rats paralyzed
1G
TABLE IV
Influence of restraint on duration of paralysis
produced by zoxazolamine in hypothermic rats
length
 —% of
	
No. o f „^ N ,	 animals
	
I	 j
	
rats	
of res- 1.1.
	 para-	 T1.	 I.r	 I ru 1	 ru
traint
	lyzed	 ^-	 ^-
	
min	 mg/1=g	 , min	 min	 1:
Free control rats
	
10	 0	 au	 IINI	 14	 1	 21 ± 1:1
	 3f,.'	 3.5
	
10	 I	 0	 4.;	 ho	 4.5	 12 4. 1.3 I	 t^.5 j 35.8
	
10	 11	 •1'1	 :hl	 5,5
	
1	 8	 36,8	 30,2
	
58	 I	 0	 -"11	 0	 _	 36.4	 -
Restrained rats
11	 t	
.n ::u	 ](RI 1
_.-
.0	 i	 (dl ;n	 j	 11 1r 1.'1 09 _^ 8 31.3 1	 32;2
Il I 	 I	 'AI	 I 111	 IINI	 j i.. 47	 IU x'1..1 3.2.:3
111	 I	 120 ill	 I	 IINI ;1_;1 1;;;	 10 7 ±1.'
I Il	 1:1.-i
10	 I	 30
iU	 I! N1 ;,ti _23 : 1 	 1. l' 1 24,? 30,3
211	 11	 I a..
111	 I	 tdl ;u	 .n	 I lU	 I 7 :11 20,5
111	 I	 40	 i Ln	 lu In	 I 24	 7 27.8 28
10	 I	 20
I
L0	 1' N I -,.2 42 1	 4 25 26
I'1	 !	 IJ:, _11	 tIN: 1.,i i,1 ± 5.5 21.3 27.8
1 0	 1_n
I
t:,	 I .-, A ^ 28	 4.5 2s 211,2
10	 12(1	 j
I	 j
;11	 I	 .kl
-1,11
i
 2-	 r. 2 LQ 24.5
TL : latency period; DP : duration of paralysis
TR 1: rectal temperature before zoxazolamine administration
TR '_: rectal temperature at end of paralysis
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TABLE V
Duration of potentialization of zoxazolamine
action by restraint, hypothermic rats.
Interval be-
tween cessa-of
tion of res-	 lanimals1 . 11 1 i '111 _	 Zoxut.lau^in.• , 	 I	 TI.	 ICI'
traint & ads	 para-
ministration _ _ lyzed I -_
N•	 of zoxazola- mr'ka	 min	 min
j 36,4 M. in e hr	 20	 0
25	 25	 I	 0	 I	 20	 l00	 5..' 	 ± 4
25	 28	 I	 1	 i	 20	 100	 I 3,6
	 24	 2
24,9	 32.2	 3	 I	 '0	 50	 4,6 1 7± 1
25,2
	34.2	 4	 20	 1	 0	 -	 I ._
0 ( rt )	 - 3715
	 I	 - I 50 100 3,5 18 -t 0,11
90 i	 31 31	 0 50 100 3,6 60 = 5.5 , )
90 V	 38.4	 5 I 50 100 3,0 i	 31	 }	 2.5 ; 1
9(1 30,5	 i 37,5	 18 50 In0	 1 3,4 28 ±	 1,61 1
(I (^) 3'•,9	 - I 50 100 3,8 132 ± 6 2
90	 29,9	 138.8	 24 I .50 100	 i 3.2 52	 o
n (^)	 37,7 50 1110 3,6 17	 21,9
135	 1 26,1	 38,4	 48
j	 i	 i
( 50 100	 1
I
3,4 24	 2,9
i
(*) I Free control rats, held at temp. conditionssame ambient
as restrained rats
TR 1 : Rectal temp. at cessation of restraint
TR 2 : Rectal temp. at moment of zoxazolamine administration
TL : Latency period
DP : Duration of paralysis
(.	 :	 P	 < 0.00 1 with respect to
— 
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TABLE VII	
Cerebral
zoxazolamine
iatencyduration of level at end
Iz""'1'eriod	 of latencyp	 paralysis	 period,min	
_ min	 µ^ R
	
20	 0	 37
normal rats
	
so	 3,2
	 21 - 2,6	 76	 s,s
	
60	
1	
2,6	 81 -_ 7	 80 t 3
stressed rats
	
20	 4,5	 42	 4	 31	 3.1
(*) zoxazolamine level determines after a time correspona ng
to the latency period of stressed animals, 4.5 min.
TABLE VIII
I	 Hypothermic
	
restrained_ rats
	
o of animals
(
( length of hyperthermia With ulcers	 index
restraint
1	 min
	
hU	 I	 31	 80	 _,_
	
411
	 27.8	 411
	
Ias	 L1,2
	
i	 PM	 i	 d
I I
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